Physician profile
Todd D Solomon
NPI 1538108063
$3,448.36
in general payments reported to CMS, 2019-2025
42 companies · $599 in 2025
The $599 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $550 · 2021: $863 · 2022: $130 · 2023: $379 · 2024: $312 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.51 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $197.09 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $195.74 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $190.99 | 2019-2025 | |
| Amgen INC. | $190.75 | 2019-2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.92 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $172.62 | 2019-2024 | Rybelsus, Ozempic |
| Grifols USA, LLC | $166.19 | 2019-2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $161.77 | 2019-2021 | |
| Astellas Pharma US INC | $135.26 | 2019-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $119.71 | 2021 | |
| Neurocrine Biosciences, INC. | $105.87 | 2025 | |
| Merck Sharp & Dohme LLC | $105.23 | 2019-2021 | |
| Glaxosmithkline, LLC. | $92.65 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $88.94 | 2019-2025 | Spravato |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.